SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
By A. O'Farrell, T. Abrams, Helene A. Yuen, T. J. Ngai, S. Louie, Kevin W. H. Yee, L. M. Wong, Weiru Hong, Leslie B. Lee, Ajia Town and 5 more. Blood, 2003
879 citations recorded by the source corpus.
Subfields: Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/82bb10e09b28bb4218710a081fa80c683643fd1a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
Citations in the corpus
- SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. (2003, background): “As an example of the former, SU11248 blocks the activity of wild-type and activated FLT3 expressed by acute myelogenous leukemia-derived cell lines (13).”
- Molecular basis for sunitinib efficacy and future clinical development (2007, result): “Interestingly, these data were consistent with those observed in patients with acute myeloid leukemia in whom exposure to sunitinib led to a sustained inhibition of FLT3 phosphorylation in blast cell”
- The discovery of receptor tyrosine kinases: targets for cancer therapy (2004, background): “The related compound SU11248 targets multiple receptor tyrosine kinase”
- SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. (2003, neutral): “Characteristic N = 22 Median (range) Age 66 (22-80) WBC (x109/L) 2.”
- The role of FLT3 in haematopoietic malignancies (2003, background): “Sugen has also identified several compounds (SU5416, SU5614 and SU11248) that block FLT3 activatio”
- Sunitinib in patients with metastatic renal cell carcinoma. (2006, neutral): “Hand-foot syndrome 9 (8) 7 (7) 0 16 (15) Nausea 14 (13) 0 0 14 ( 13 )”
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia (2011, background): “g, Ribbon representation of the BRD4-BD1 (cyan) crystal structure complexed with I-BET151 (shown in magenta stick format) overlaid with H3(12-19)K14ac peptide (green) taken from its complex with BRD4-BD1(PDB ID 3jvk).”